Literature DB >> 3489062

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

J H Phillips, L L Lanier.   

Abstract

In vitro culture of human peripheral blood lymphocytes in IL-2 results in the generation of cytotoxic cells that can lyse fresh and cultured solid tumor cells, as well as hematopoietic tumor cell lines, without deliberate immunization or MHC restriction. This has been referred to as the lymphokine activated killer (LAK) phenomenon. Here, we show that the majority of this activity is mediated by NK cells that express the Leu-19 (NKH-1) antigen, but do not express CD3. The precursor of this effector population also expressed the phenotype CD3-, Leu-19+. Peripheral blood CD3+ T lymphocytes contributed little to the LAK phenomenon, although low levels of non-MHC restricted cytotoxicity against hematopoietic tumor cell targets were mediated by a subset of CD3+ T lymphocytes that coexpressed the Leu-19 antigen. These studies clearly indicated that the LAK phenomenon is not mediated by a unique LAK cell, but is mediated mainly by IL-2-activated peripheral blood NK cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489062      PMCID: PMC2188384          DOI: 10.1084/jem.164.3.814

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.

Authors:  L L Lanier; A M Le; C I Civin; M R Loken; J H Phillips
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

2.  Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.

Authors:  K Itoh; A B Tilden; K Kumagai; C M Balch
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

3.  A monoclonal antibody blocking human T cell function.

Authors:  E L Reinherz; R E Hussey; S F Schlossman
Journal:  Eur J Immunol       Date:  1980-10       Impact factor: 5.532

4.  Induction of natural killer-like cytotoxicity in cultured human thymocytes.

Authors:  M L Toribio; M O De Landázuri; M López-Botet
Journal:  Eur J Immunol       Date:  1983-12       Impact factor: 5.532

5.  Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.

Authors:  L L Lanier; C J Benike; J H Phillips; E G Engleman
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

6.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.

Authors:  L L Lanier; A M Le; J H Phillips; N L Warner; G F Babcock
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

7.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

8.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

9.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

Authors:  E A Grimm; R J Robb; J A Roth; L M Neckers; L B Lachman; D J Wilson; S A Rosenberg
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more
  165 in total

1.  Clinical significance of changes of perioperative T cell and expression of its activatedantigen in colorectal cancer patients.

Authors:  Yi-Xing Wang; Can-Ping Ruan; Li Li; Jing-Hua Shi; Xian-Tao Kong
Journal:  World J Gastroenterol       Date:  1999-04       Impact factor: 5.742

2.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

3.  Functional impairment of natural killer cells in active ulcerative colitis: reversion of the defective natural killer activity by interleukin 2.

Authors:  L Manzano; M Alvarez-Mon; L Abreu; J Antonio Vargas; E de la Morena; F Corugedo; A Duràntez
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

4.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Human interleukin-2 activated cytotoxic cells kill autologous glioma cells in vitro.

Authors:  V Bosnes; H Hirschberg
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

6.  Short-term lymphokine stimulation of human peripheral blood mononuclear cells generates cytolytic activity against endothelial cells: involvement of natural killer cells.

Authors:  A M Miltenburg; M E Meijer-Paape; M R Daha; L C Paul
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

7.  Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.

Authors:  M Suzuki; T Kikuchi; F Takatsuki; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

8.  Expansion of CD56+ NK T and gamma delta T cells from cord blood of human neonates.

Authors:  N Musha; Y Yoshida; S Sugahara; S Yamagiwa; T Koya; H Watanabe; K Hatakeyama; T Abo
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

9.  Changes in natural immunity during the course of HIV-1 infection.

Authors:  B G Brenner; C Gryllis; M Gornitsky; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

10.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.